MedTrace Logo

Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness

NCT00545675 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2010-08-12

No results posted yet for this study

Summary

To demonstrate the difference between Abilify with Depakote vs. Placebo with Depakote in 24-week treatment in patients with remission status after Abilify with Depakote in the 6-week study of acute mania in patients with bipolar disorder

Conditions

Interventions

DRUG

Abilify(aripiprazole)

Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder

DRUG

Depakote (divalproate)

Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder

Sponsors & Collaborators

  • Korea Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Won-Myong Bahk, MD · St Mary's Hospital, London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00545675 on ClinicalTrials.gov